International health emergencies expose health data infrastructure gaps. 10 COVID-19 driver projects reveal data challenges and lessons for future preparedness.
How RWD and RWE advance clinical pharmacology and translational research — guidance on data access, quality assessment, and governance for RWD programmes.
Paper an AI approach to generating MIDD assets across the drug development continuum
AI for generating MIDD assets across the drug development continuum. Model-informed drug development, PK/PD modelling, and AI-assisted regulatory submissions.
Question-centric regulatory decision-making in drug assessment. Aligning evidence generation, submission strategy, and regulatory dialogue in drug development.
Systems biology and QSP for drug development in pregnancy. Addressing pharmacokinetic, pharmacodynamic, and safety knowledge gaps in maternal medicine.
The Aridhia DRE enables AI across early-stage drug development: target identification, virtual screening, PKPD modelling, and candidate selection, securely.
The future of rare disease drug development
How RDCA-DAP is transforming rare disease drug development: Collaborative analytics, FAIR data, and secure research infrastructure powered by the Aridhia DRE.
Training the next generation of pharmacometric modelers a multisector perspective
harmacometric modeller training - a multisector perspective on the skills, tools, and frameworks shaping the next generation of pharmacometricians.
The precompetitive space for drug or vaccine development
How competing pharmaceutical organisations collaborate on shared drug development challenges without sacrificing competitive advantage.
tachykinin receptors in gtopdb v 2023 1
Tachykinin receptors in GtoPdb 2023.1 — NC-IUPHAR nomenclature, substance P, neurokinin A and B, and approved antagonists.
